New drug combo targets Hard-to-Treat head and neck cancers
NCT ID NCT05721443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—cetuximab and dalpicilib—in people with a type of head and neck cancer that has returned or spread and no longer responds to standard immunotherapy. The study includes 28 adults aged 18 to 75 whose tumors are HPV-negative. The goal is to see if this drug pair can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cetuximab and dalpicilib
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with head and neck cancer that has stopped responding to immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to all patients. The drugs can cause side effects like infusion reactions and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle recurrent head and neck cancer
- Promising drug cocktail targets Hard-to-Treat head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancer
- New hope for head and neck cancer: drug combo shows promise after standard treatment fails
- Promising combo therapy for head and neck cancer hits early snag
- Gut health boost may tame immunotherapy side effects in head and neck cancer